Direxion Daily Pharmaceutical & Medical Bull 3X Shares
PILL$12.71 -0.28 (-2.16%)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2025 | $0.03 | 2025-12-23 | 2025-12-23 |
| September 30, 2025 | $0.01 | 2025-09-23 | 2025-09-23 |
| July 1, 2025 | $0.02 | 2025-06-24 | 2025-06-24 |
| April 1, 2025 | $0.02 | 2025-03-25 | 2025-03-25 |
| December 31, 2024 | $0.01 | 2024-12-23 | 2024-12-23 |
Dividends Summary
- Consistent Payer: Direxion Daily Pharmaceutical & Medical Bull 3X Shares has rewarded shareholders with 25 dividend payments over the past 8 years.
- Total Returned Value: Investors who held PILL shares during this period received a total of $0.68 per share in dividend income.
- Latest Payout: The most recent dividend of $0.03/share was paid 23 days ago, on December 31, 2025.
- Yield & Schedule: PILL currently pays dividends quarterly with an annual yield of 0.67%.
- Dividend Growth: Since 2017, the dividend payout has grown by 141.7%, from $0.01 to $0.03.
Company News
The Zacks Analyst Blog Highlights AdvisorShares MSOS 2x Daily ETF, ProShares Ultra Semiconductors, BMO REX MicroSectors FANG+ Index 3X Leveraged ETN, Direxion Daily Pharmaceutical & Medical Bull 3X Shares and Direxion Daily Semiconductor Bull 3x Shar
AdvisorShares MSOS 2x Daily ETF, ProShares Ultra Semiconductors, BMO REX MicroSectors FANG+ Index 3X Leveraged ETN, Direxion Daily Pharmaceutical & Medical Bull 3X Shares and Direxion Daily Semiconductor Bull 3x Shares are included in this Analyst Blog.
5 Best Leveraged ETFs of First Half of Q1
We highlight a bunch of the best-performing leveraged equity ETFs from different corners of the market that are leaders in their segments in the first half of Q1.
5 Best Inverse/Leveraged ETFs of Last Week
The optimism surrounding the likely Fed rate cuts in 2024 aided the rally in the market last week, barring some occasional dips.
Best Leveraged ETF Areas of Last Week
Wall Street was at the record high last week due to upbeat corporate earnings, strong jobs data and Pfizer's pill study.
